Personalized mRNA Vaccine Shows Promise in Treating Triple-Negative Breast Cancer

Thousands of women are diagnosed with triple-negative breast cancer (TNBC) each year, one of the most aggressive and hard-to-treat forms of the disease. Despite surgery, chemotherapy, and radiation therapy, the risk of relapse remains high. Now, an international research team has published initial results in Nature demonstrating the potential of a personalized messenger RNA (mRNA) vaccine to activate the immune system to recognize and eliminate tumor cells.

How the Personalized Vaccine Works

Unlike preventative vaccines, this mRNA vaccine is designed for the specific treatment of each patient’s cancer. The process begins with sequencing the patient’s tumor to identify up to 20 neoantigens – unique markers found on the cancer cells. These neoantigens are then incorporated into an mRNA formula, which instructs the immune system to recognize and attack the malignant cells. The goal is to bolster the immune system’s ability to fight the tumor and prevent future relapses, as explained by Ugur Sahin .

Each vaccine is custom-made, typically within an average of 69 days from the biopsy, to match the specific mutations of the treated tumor. Patients receive eight standard doses after surgery and chemotherapy, integrating immunization as a complement to conventional treatments.

Clinical Trial Results

The clinical trial showed that all participants developed T cell responses to one or more of their vaccine neoantigens. Nine of the 14 women treated exhibited reactivity against at least five different neoantigens. 86% of the responses were detectable by specific tests, reaching levels comparable to those seen with adoptive cell therapies .

Importantly, these specific T lymphocytes demonstrated “the ability to act and long-term memory,” remaining functional in the peripheral blood for more than six years after vaccination, without the need for booster doses. This suggests the potential for lasting immunity .

Safety and Feasibility

The vaccine demonstrated a favorable safety profile, with most adverse effects being mild and temporary, such as fever, headache, or fatigue. Only one patient discontinued treatment due to moderate symptoms. The production and administration process proved viable under clinical practice conditions, overcoming logistical and time challenges associated with creating a unique medicine for each person.

Addressing Tumor Escape and Future Directions

While most patients remained relapse-free, researchers identified tumor escape mechanisms in three women who experienced recurrences. These mechanisms included an insufficient immune response, loss of MHC-I expression in the recurrent tumor, or the emergence of a second tumor with mutations not included in the original vaccine . These findings highlight the need for combined strategies and potentially sequencing multiple tumor sites in high-risk patients.

The BioNTech team is now developing phase II clinical trials with similar vaccines for colon, pancreatic, and bladder cancer. If results remain promising, the company anticipates that a personalized mRNA vaccine against some types of cancer could be approved for medical use by 2030.

Comparing to Current Immunotherapies

Currently, treatments like Pembrolizumab are used for triple-negative breast cancer in tumors considered “hot” (PD-L1 positive), aiming to reactivate antitumor activity in cancers that have evaded the immune system. The potential of this vaccine lies in its ability to target “cold” tumors – those that don’t respond to conventional immunotherapy because they are invisible to the immune system. By identifying specific neoantigens through tumor sequencing, the vaccine aims to activate the immune defenses and transform “cold” tumors into “hot” tumors, enabling the immune system to recognize and eliminate cancer cells .

Further validation through larger, comparative studies is essential to confirm the vaccine’s effectiveness and identify any potential, previously undetected toxicities.